|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:capacity
|
10 m L
|
|
gptkbp:clinical_trial
|
NCT00299999
NCT00320000
NCT00412345
NCT00512345
|
|
gptkbp:clinical_use
|
long-term prophylaxis
|
|
gptkbp:contraindication
|
history of severe allergic reactions
hypersensitivity to C1 esterase inhibitor
|
|
gptkbp:dosage_form
|
lyophilized powder for reconstitution
|
|
gptkbp:effective_date
|
2008-10-07
|
|
gptkbp:financial_support
|
available
|
|
gptkbp:formulation
|
sterile solution
|
|
gptkbp:frequency
|
every 3 to 4 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cinryze
|
|
gptkbp:indication
|
gptkb:hereditary_angioedema
|
|
gptkbp:ingredients
|
gptkb:C1_esterase_inhibitor
|
|
gptkbp:label
|
FDA approved labeling
|
|
gptkbp:manufacturer
|
gptkb:Viro_Pharma
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:packaging
|
single-use vial
|
|
gptkbp:patient_population
|
adults and children over 2 years
|
|
gptkbp:pharmacokinetics
|
replenishes C1 inhibitor levels
half-life of approximately 60 hours
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_guidance_on
|
recommended in HAE management
|
|
gptkbp:reconstitution_instructions
|
dilute with sterile water for injection
|
|
gptkbp:related_products
|
gptkb:Berinert
gptkb:Firazyr
gptkb:Haegarda
gptkb:Icatibant
|
|
gptkbp:research
|
ongoing studies for new indications
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
urticaria
diarrhea
thromboembolic events
anaphylaxis
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:type_of_insurance
|
may be covered by health insurance
|
|
gptkbp:used_for
|
prevention of angioedema attacks
|
|
gptkbp:bfsParent
|
gptkb:Shire_plc
|
|
gptkbp:bfsLayer
|
5
|